Abstract: The present invention is directed to novel calcium and/or magnesium chelated bisphosphonates, which have improved bioavailability, and less irritation in the GI tract. These bioactive chelated bisphosphonates are useful to treat osteoporosis and other medical disorders previously suggested in the literature.

Abstract: This invention describes new and novel bisphosphonate conjugates having anti-inflammatory and/or pain-killing properties.

Abstract: The present invention is directed to novel and new oral parenteral compositions comprising various bisphosphonates in conjunction with bound or unbound ion exchange resins, or mixtures of the two types of resins thereof. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract in humans or animals prohibiting the exposure of the bisphosphonates to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach. These drug-resinates also have the systemic effect of providing a slow release mechanism, thereby extending the efficacy of the treatment for a longer period of time. The drug resinates can also incorporate ionic charged bioactive molecules containing carboxylate, amino or positively charged amino groups having synergistic value in conjunction with bisphosphonates.